{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,22]],"date-time":"2026-11-22T03:42:55Z","timestamp":1795318975796,"version":"4.10.3"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","award":["ISR-ES-19-10727"],"award-info":[{"award-number":["ISR-ES-19-10727"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ijantimicag.2024.107164","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T15:37:27Z","timestamp":1712072247000},"page":"107164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Bictegravir\/emtricitabine\/tenofovir alafenamide as first-line treatment in na\u00efve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-5728","authenticated-orcid":false,"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Sequera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9373-6011","authenticated-orcid":false,"given":"Mar\u00eda Jesus","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5663-8447","authenticated-orcid":false,"given":"David","family":"Vinuesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-8170","authenticated-orcid":false,"given":"Antonio","family":"Collado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7073-5211","authenticated-orcid":false,"given":"Ignacio De Los","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Cabello-Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Ramos","family":"Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Terron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onofre","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Omar-Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-7476","authenticated-orcid":false,"given":"Helena","family":"Albend\u00edn-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Javier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel L\u00f3pez-","family":"Ruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1345-4901","authenticated-orcid":false,"given":"Alberto","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Garcia-Vallecillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107164_bib0001","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/imj.15739","article-title":"HIV: the changing paradigm","volume":"52","author":"Raubinger","year":"2022","journal-title":"Intern Med J"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0002","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.2018.21167","article-title":"HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable","volume":"321","author":"Eisinger","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0003","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Lundgren","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0004","doi-asserted-by":"crossref","first-page":"e25419","DOI":"10.1002\/jia2.25419","article-title":"Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review","volume":"22","author":"Elliott","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0005","unstructured":"European AIDS Clinical Society. EACS European Guidelines for treatment of HIV infected adults in Europe. versi\u00f3n 12. 2023. https:\/\/eacs.sanfordguide.com."},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0006","unstructured":"Documento de consenso de GeSIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. GRUPO ESPA\u00d1OL PARA EL ESTUDIO DEL SIDA (GESIDA) https:\/\/gesida-seimc.org\/category\/guias-clinicas; 2023."},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0007","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0008","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief Report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0009","first-page":"242","article-title":"Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks","volume":"22","author":"Sutton","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","article-title":"EQ-5D and the EuroQol group: past, present and future","volume":"15","author":"Devlin","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0011","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","article-title":"GEEMA study group validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study","volume":"16","author":"Knobel","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0012","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.3390\/diagnostics12112590","article-title":"The relationship between visceral adiposity and nonalcoholic fatty liver disease diagnosed by controlled attenuation parameter in people with HIV: a pilot study","volume":"12","author":"Sebastiani","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0013","first-page":"57","article-title":"Intention to treat: once randomized, always analyzed","volume":"23","author":"Wertz","year":"1995","journal-title":"Clin Aphasiol"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0014","doi-asserted-by":"crossref","first-page":"c2697","DOI":"10.1136\/bmj.c2697","article-title":"Modified intention to treat reporting in randomised controlled trials: systematic review","volume":"340","author":"Abraha","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0015","series-title":"Analysis issues, ITT, post-hoc, and subgroups","author":"Day","year":"2008"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0016","first-page":"81","article-title":"How much should I weigh? Quetelet\u00b4s equation, upper weight limits, and BMI prime","volume":"70","author":"Gadzik","year":"2006","journal-title":"Conn Med"},{"issue":"suppl 1","key":"10.1016\/j.ijantimicag.2024.107164_bib0017","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0895-4356(01)00449-8","article-title":"Development and validation of a self-completed HIV symptom index","volume":"54","author":"Justice","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0018","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1477-7525-11-164","article-title":"Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review","volume":"11","author":"Simpson","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0019","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/dkl092","article-title":"HIV-1 viral load blips are of limited clinical significance","volume":"57","author":"Lee","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0020","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/infdis\/jis104","article-title":"Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis","volume":"205","author":"Grennan","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0021","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide: a review in HIV-1 infection","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0022","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1093\/cid\/ciz1213","article-title":"Darunavir\/cobicistat\/ emtricitabine\/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: primary analysis of the DIAMOND study","volume":"71","author":"Huhn","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0023","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0000000000002979","article-title":"Dolutegravir\/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV","volume":"35","author":"Rolle","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0024","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/dkad008","article-title":"Same-day initiation of bictegravir\/emtricitabine\/tenofovir alafenamide: week 48 results of the FAST study-IMEA 055","volume":"78","author":"Bachelard","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0025","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0026","article-title":"GS-US-380- 1489 and GS-US-380-1490 study investigators. Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QAD.0000000000001671","article-title":"Benefits and risks of rapid initiation of antiretroviral therapy","volume":"32","author":"Ford","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0028","unstructured":"World Health Organization. The role of HIV viral suppression in improving individual health and reducing transmission. 2023. https:\/\/www.who.int\/es\/publications\/i\/item\/9789240055179."},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0029","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0000000000002124","article-title":"RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population","volume":"33","author":"Coffey","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0030","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0031","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107164_bib0032","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/dkad007","article-title":"Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort","volume":"78","author":"Grabar","year":"2023","journal-title":"J Antimicrob.Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924000827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924000827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T16:52:18Z","timestamp":1716828738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0924857924000827"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107164","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bictegravir\/emtricitabine\/tenofovir alafenamide as first-line treatment in na\u00efve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107164"}}